Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 24

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 24
---
 security situation in Israel; and |

| ● | those factors referred to in our 2024 Annual Report incorporated by reference herein in “Item 3. Key Information – D. Risk Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and Financial Review and Prospects,” as well as in our 2024 Annual Report generally, which is incorporated by reference into this prospectus. |

Forward-looking statements
are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in
which we operate and our management’s beliefs and assumptions, and are not guarantees of future performance or development and involve
known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking
statements in this prospectus may turn out to be inaccurate. Important factors that may cause actual results to differ materially from
current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this prospectus or any
accompanying prospectus supplement. Potential investors are urged to consider these factors carefully in evaluating the forward-looking
statements.

Further, any forward-looking
statement speaks only as of the date on which it is made. Although we believe that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these
forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors
and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See “Where You
Can Find More Information.”

<div align='center'>S-11

CAPITALIZATION</div>

The following table sets forth our cash and our
capitalization as of July 31, 2025:

| ● | on an actual basis; and |

| ● | on                                                                                                                                             
 pro forma basis, giving effect to the issuance of (i) Promissory Notes in the aggregate principal amount of $2.5 million, of which an          
 aggregate of $2.5 million of outstanding amounts due under the Promissory Notes were converted into 5,171,460 Common Shares at conversion      
 prices between $0.251 and $0.818, (ii) the